Literature DB >> 7919540

Functional analysis of the AUG- and CUG-initiated forms of the c-Myc protein.

E M Blackwood1, T G Lugo, L Kretzner, M W King, A J Street, O N Witte, R N Eisenman.   

Abstract

Activation of the c-myc proto-oncogene by chromosomal translocation or proviral insertion frequently results in the separation of the c-myc coding region from its normal regulatory elements. Such rearrangements are often accompanied by loss or mutation of c-myc exon 1 sequences. These genetic alterations do not affect synthesis of the major c-myc protein, p64, which is initiated from the first AUG codon in exon 2. However they can result in mutation or loss of the CUG codon located in exon 1 that normally serves as an alternative translational initiation codon for synthesis of an N-terminally extended form of c-Myc (p67). It has been hypothesized that p67 is a functionally distinct form of c-Myc whose specific loss during c-myc rearrangements confers a selective growth advantage. Here we describe experiments designed to test the functional properties of the two c-Myc protein forms. We introduced mutations within the translational initiation codons of a normal human c-myc cDNA that alter the pattern of Myc protein synthesis (p64 vs. p67). The functions of each of these proteins were experimentally addressed using co-transformation and transcriptional activation assays. Both the p64 and p67 c-Myc proteins were independently able to collaborate with bcr-abl in the transformation of Rat-1 fibroblasts. In addition, both the exon 1- and exon 2-initiated forms of the c-Myc protein stimulated transcription of a Myc/Max-responsive reporter construct to a similar level. Given the apparent absence of functional differences between p64 and p67, we conclude that the basis for c-Myc oncogenic activation lies primarily in the overall deregulation of its expression and not in alterations in the protein. The existence of the CUG translational initiator may reflect a mechanism for the continued synthesis of c-Myc protein under conditions where AUG initiation is inhibited.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7919540      PMCID: PMC301071          DOI: 10.1091/mbc.5.5.597

Source DB:  PubMed          Journal:  Mol Biol Cell        ISSN: 1059-1524            Impact factor:   4.138


  79 in total

1.  Proteins encoded by the human c-myc oncogene: differential expression in neoplastic cells.

Authors:  S R Hann; R N Eisenman
Journal:  Mol Cell Biol       Date:  1984-11       Impact factor: 4.272

2.  Stimulation of 3T3 cells induces transcription of the c-fos proto-oncogene.

Authors:  M E Greenberg; E B Ziff
Journal:  Nature       Date:  1984 Oct 4-10       Impact factor: 49.962

3.  Cell-specific regulation of the c-myc gene by lymphocyte mitogens and platelet-derived growth factor.

Authors:  K Kelly; B H Cochran; C D Stiles; P Leder
Journal:  Cell       Date:  1983-12       Impact factor: 41.582

4.  Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas.

Authors:  K Bhatia; K Huppi; G Spangler; D Siwarski; R Iyer; I Magrath
Journal:  Nat Genet       Date:  1993-09       Impact factor: 38.330

5.  Association of amplified oncogene c-myc with an abnormally banded chromosome 8 in a human leukaemia cell line.

Authors:  P Nowell; J Finan; R Dalla-Favera; R C Gallo; A ar-Rushdi; H Romanczuk; J R Selden; B S Emanuel; G Rovera; C M Croce
Journal:  Nature       Date:  1983 Dec 1-7       Impact factor: 49.962

6.  Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells.

Authors:  C M Gorman; L F Moffat; B H Howard
Journal:  Mol Cell Biol       Date:  1982-09       Impact factor: 4.272

7.  Genomic alterations involving the c-myc proto-oncogene locus during the evolution of a case of chronic granulocytic leukaemia.

Authors:  D M McCarthy; F V Rassool; J M Goldman; S V Graham; G D Birnie
Journal:  Lancet       Date:  1984-12-15       Impact factor: 79.321

8.  Levels of c-myc oncogene mRNA are invariant throughout the cell cycle.

Authors:  C B Thompson; P B Challoner; P E Neiman; M Groudine
Journal:  Nature       Date:  1985 Mar 28-Apr 3       Impact factor: 49.962

9.  Proteins encoded by v-myc and c-myc oncogenes: identification and localization in acute leukemia virus transformants and bursal lymphoma cell lines.

Authors:  S R Hann; H D Abrams; L R Rohrschneider; R N Eisenman
Journal:  Cell       Date:  1983-10       Impact factor: 41.582

10.  Chromosomal translocations activating myc sequences and transduction of v-abl are critical events in the rapid induction of plasmacytomas by pristane and abelson virus.

Authors:  S Ohno; S Migita; F Wiener; M Babonits; G Klein; J F Mushinski; M Potter
Journal:  J Exp Med       Date:  1984-06-01       Impact factor: 14.307

View more
  10 in total

1.  Expansion of the (CTG)(n) repeat in the 5'-UTR of a reporter gene impedes translation.

Authors:  G Raca; E Y Siyanova; C T McMurray; S M Mirkin
Journal:  Nucleic Acids Res       Date:  2000-10-15       Impact factor: 16.971

2.  c-Myc promotes differentiation of human epidermal stem cells.

Authors:  A Gandarillas; F M Watt
Journal:  Genes Dev       Date:  1997-11-01       Impact factor: 11.361

3.  Activation of the myc oncoprotein leads to increased turnover of thrombospondin-1 mRNA.

Authors:  A Janz; C Sevignani; K Kenyon; C V Ngo; A Thomas-Tikhonenko
Journal:  Nucleic Acids Res       Date:  2000-06-01       Impact factor: 16.971

Review 4.  MYC on the path to cancer.

Authors:  Chi V Dang
Journal:  Cell       Date:  2012-03-30       Impact factor: 41.582

5.  Disruption of Myc-tubulin interaction by hyperphosphorylation of c-Myc during mitosis or by constitutive hyperphosphorylation of mutant c-Myc in Burkitt's lymphoma.

Authors:  J Niklinski; G Claassen; C Meyers; M A Gregory; C J Allegra; F J Kaye; S R Hann; M Zajac-Kaye
Journal:  Mol Cell Biol       Date:  2000-07       Impact factor: 4.272

6.  Naturally occurring dicistronic cricket paralysis virus RNA is regulated by two internal ribosome entry sites.

Authors:  J E Wilson; M J Powell; S E Hoover; P Sarnow
Journal:  Mol Cell Biol       Date:  2000-07       Impact factor: 4.272

7.  Dual regulation of Myc by Abl.

Authors:  V J Sanchez-Arévalo Lobo; M Doni; A Verrecchia; S Sanulli; G Fagà; A Piontini; M Bianchi; M Conacci-Sorrell; G Mazzarol; V Peg; J H Losa; P Ronchi; M Ponzoni; R N Eisenman; C Doglioni; B Amati
Journal:  Oncogene       Date:  2013-01-14       Impact factor: 9.867

Review 8.  MYC-induced cancer cell energy metabolism and therapeutic opportunities.

Authors:  Chi V Dang; Anne Le; Ping Gao
Journal:  Clin Cancer Res       Date:  2009-10-27       Impact factor: 12.531

9.  Quantitative proteomic analysis of Myc oncoprotein function.

Authors:  Yuzuru Shiio; Sam Donohoe; Eugene C Yi; David R Goodlett; Ruedi Aebersold; Robert N Eisenman
Journal:  EMBO J       Date:  2002-10-01       Impact factor: 11.598

Review 10.  Translation acrobatics: how cancer cells exploit alternate modes of translational initiation.

Authors:  Ashwin Sriram; Jonathan Bohlen; Aurelio A Teleman
Journal:  EMBO Rep       Date:  2018-09-17       Impact factor: 8.807

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.